Aucatzyl — obecabtagene autoleucel
Named-patient access overview. Aucatzyl is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Aucatzyl
Aucatzyl (obecabtagene autoleucel) is manufactured by Autolus and indicated for Adult R/R B-ALL. It is a CAR-T (CD19 fast-off) approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Aucatzyl
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Aucatzyl for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Aucatzyl is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Aucatzyl in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Aucatzyl in BangladeshNamed-patient access, timeline, and regulatory notes
Aucatzyl in IndiaNamed-patient access, timeline, and regulatory notes
Aucatzyl in JordanNamed-patient access, timeline, and regulatory notes
Aucatzyl in KuwaitNamed-patient access, timeline, and regulatory notes
Aucatzyl in NepalNamed-patient access, timeline, and regulatory notes
Aucatzyl in Sri LankaNamed-patient access, timeline, and regulatory notes
Aucatzyl in United Arab EmiratesNamed-patient access, timeline, and regulatory notes
Start a request for Aucatzyl
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.